论文部分内容阅读
肺炎球菌表面蛋白A(PspA)是一种抗肺炎链球菌的构成蛋白疫苗的很有希望的候选物。之前我们已经表明,全细胞百日咳疫苗(wP)对于PspA是一种很好的佐剂,在小鼠中诱导抗肺炎球菌感染的保护性应答。在巴西,wP与白喉、破伤风类毒素(DTPw)及氢氧化铝(明矾)佐剂一起施用于儿童。在小鼠中PspA5-DTP.的单一皮下注射剂量(配方包含得自进化支5的PspA和新一代DTPw,并含有低剂量的百日咳杆菌脂多糖和明矾)诱导高水平的全身PspA5抗体,并针对两种不同的呼吸道致命性肺
Pneumococcal surface protein A (PspA) is a promising candidate for the construction of protein vaccines against S. pneumoniae. We have previously shown that the whole-cell pertussis vaccine (wP) is a good adjuvant for PspA and induces a protective response against pneumococcal infection in mice. In Brazil, wP is administered to children with diphtheria, tetanus toxoid (DTPw), and aluminum hydroxide (alum) adjuvants. A single subcutaneous injection of PspA5-DTP. In mice, formulated with PspA from Clade 5 and a new generation of DTPw and low doses of Bordetella pertussis lipopolysaccharide and alum, induces high levels of systemic PspA5 antibody against Two different respiratory fatal lungs